20/20 Biolabs, Inc. (AIDX) Stock Statistics & Valuation Metrics

20/20 Biolabs, Inc. has a market cap or net worth of $4.50M. The enterprise value is $4.30M.

20/20 Biolabs, Inc. has 12,770,303 shares outstanding. The number of shares has decreased by -2.65% in one year.

20/20 Biolabs, Inc.’s return on equity (ROE) is 194.48 and return on invested capital (ROIC) is -1.87%.

The current PE Ratio of 20/20 Biolabs, Inc. is ―. 20/20 Biolabs, Inc.’s PEG ratio is 0.82.

In the last 12 months, 20/20 Biolabs, Inc. had revenue of 2.05M and earned -3.74M in profits. Earnings per share was -0.60.

In the last 12 months, operating cash flow was -2.79M and capital expenditures 5.35K, giving a free cash flow of -2.79M billion.

20/20 Biolabs, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

20/20 Biolabs, Inc. upcoming earnings date is Aug 17, 2026, After Close (Confirmed).

20/20 Biolabs, Inc. as a current ratio of 0.60, with Debt / Equity ratio of 18.12%

In the past 12 months, 20/20 Biolabs, Inc. has paid 0.00 in taxes.

20/20 Biolabs, Inc. EV to EBITDA ratio is -116.21, with an EV/FCF ratio of -0.21.

20/20 Biolabs, Inc. has $4.55M in cash and marketable securities with $572.45K in debt, giving a net cash position of $3.97M billion.

Gross margin is 31.52%, with operating margin of -162.87%, and net profit margin of -182.82%.

The average price target for 20/20 Biolabs, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy